학술논문

GFAP mutations, age at onset, and clinical subtypes in Alexander disease
Document Type
article
Source
Neurology. 77(13)
Subject
Neurosciences
Clinical Research
Brain Disorders
Neurodegenerative
Genetics
Rare Diseases
Aetiology
2.1 Biological and endogenous factors
Adolescent
Adult
Age Factors
Age of Onset
Alexander Disease
Bayes Theorem
DNA Mutational Analysis
Exons
Female
Glial Fibrillary Acidic Protein
Humans
Logistic Models
Male
Mutation
Retrospective Studies
Survival Analysis
Young Adult
Clinical Sciences
Cognitive Sciences
Neurology & Neurosurgery
Language
Abstract
ObjectiveTo characterize Alexander disease (AxD) phenotypes and determine correlations with age at onset (AAO) and genetic mutation. AxD is an astrogliopathy usually characterized on MRI by leukodystrophy and caused by glial fibrillary acidic protein (GFAP) mutations.MethodsWe present 30 new cases of AxD and reviewed 185 previously reported cases. We conducted Wilcoxon rank sum tests to identify variables scaling with AAO, survival analysis to identify predictors of mortality, and χ(2) tests to assess the effects of common GFAP mutations. Finally, we performed latent class analysis (LCA) to statistically define AxD subtypes.ResultsLCA identified 2 classes of AxD. Type I is characterized by early onset, seizures, macrocephaly, motor delay, encephalopathy, failure to thrive, paroxysmal deterioration, and typical MRI features. Type II is characterized by later onset, autonomic dysfunction, ocular movement abnormalities, bulbar symptoms, and atypical MRI features. Survival analysis predicted a nearly 2-fold increase in mortality among patients with type I AxD relative to those with type II. R79 and R239 GFAP mutations were most common (16.6% and 20.3% of all cases, respectively). These common mutations predicted distinct clinical outcomes, with R239 predicting the most aggressive course.ConclusionsAAO and the GFAP mutation site are important clinical predictors in AxD, with clear correlations to defined patterns of phenotypic expression. We propose revised AxD subtypes, type I and type II, based on analysis of statistically defined patient groups.